The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not pro [...]
It’s been a rough time for Peloton. Last year was marred by deep staff cuts, a change of CEO and a reckoning of where the home fitness company belonged, post-Pandemic boom. The answer is, unfortunat [...]